2 results
Approved WMORecruiting
To determine non inferiority of two doses of BI 10773 (10 mg/daily and 25 mg/daily) compared to placebo with respect to first occurrence of any of the adjudicated components of the primary composite Major Adverse Cardiovascular Event endpoint (…
Approved WMORecruiting
- Confirming the survivorship under normal use of the Collared and Collarless versions of the Avenir Complete* stem (Standard, High Offset, Coxa Vara) and its instrumentation used in primary total, hemi, or revision hip arthroplasty by recording the…